Hims & Hers Health (NYSE:HIMS) Stock Price Down 8.2% - Should You Sell?
Hims & Hers Health (NYSE:HIMS) stock fell 8.2% to $41.39, with trading volume down 57% from average levels. Analysts have mixed ratings, with two sell, seven hold, and six buy ratings. The average target price is $37.23. The company reported $0.11 EPS, beating estimates, but revenue of $481.14 million fell short of expectations. Insider selling has been noted, with significant shares sold recently. Hedge funds have also been active, with new positions and increased stakes reported in the last quarter.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was down 8.2% on Monday . The company traded as low as $42.19 and last traded at $41.39. Approximately 9,467,116 shares changed hands during trading, a decline of 57% from the average daily volume of 22,015,939 shares. The stock had previously closed at $45.09.
Get Hims & Hers Health alerts:
Wall Street Analysts Forecast Growth
- Missed the Hims & Hers Rally? Clover Health Could Be Next
Several research firms have issued reports on HIMS. Truist Financial lifted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a research note on Wednesday, February 26th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Citigroup increased their target price on shares of Hims & Hers Health from $25.00 to $27.00 and gave the company a "sell" rating in a research report on Tuesday, February 25th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Finally, Bank of America increased their price objective on Hims & Hers Health from $18.00 to $21.00 and gave the company an "underperform" rating in a report on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and a consensus price target of $37.23.
Read Our Latest Report on Hims & Hers Health
Hims & Hers Health Stock Performance
- Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now
The firm's 50 day simple moving average is $36.57 and its 200 day simple moving average is $26.82. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of 92.39 and a beta of 1.35.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Insider Buying and Selling
- MarketBeat Week in Review – 02/17 - 02/21
In other news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares of the company's stock, valued at $2,885,801.88. This represents a 8.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $48.14, for a total value of $832,966.42. Following the transaction, the insider now owns 193,601 shares of the company's stock, valued at approximately $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. Company insiders own 17.71% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its stake in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.
About Hims & Hers Health
(Get Free Report)Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- Pros And Cons Of Monthly Dividend Stocks
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Hims & Hers Health Right Now?
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
